Patients previously treated with irinotecan are eligible for this study
Patients may or may not have been treated previously with a nonsteroidal antiandrogen, such as flutamide, bicalutamide or nilutamide; for patients previously treated with an antiandrogen, they must be off treatment for at least  weeks (for flutamide) or  weeks (for bicalutamide or nilutamide) prior to registration and must have shown PSA progression after discontinuing the anti-androgen
Patients previously treated with CVA.
Patients who have been previously treated with a toll-like receptor (TLR) agonist (excluding topical agents) and patients who have received experimental cancer vaccines.
Patients who previously discontinued trastuzumab due to unacceptable cardiac toxicity
Patients must not have been previously treated with lorlatinib.
Among patients with multiple sites of metastatic disease, the other sites that will not be treated on this protocol have either been previously treated or are planned for local treatment
Subject who has been previously treated with an anti-CCR antibody or an IDO inhibitor;
Transfusion-dependence in subjects previously treated with an ESA (requires a minimum ESA trial of > , U/week recombinant human erythropoietin (rHuEPO) x  weeks or equivalent dose of darbepoetin or other erythropoietin agent), or
Serum erythropoietin level of >  mU/mL in subjects not previously treated with an ESA.
Have previously received TB-
At least  months since completion of curative therapy, if given previously
Patient previously treated with a dose of imatinib > mg
The majority of the anticipated target volume (> %) must have been previously treated to >=  Gy; prior radiation therapy (RT) must have been completed >  months prior to initiation of IMRT reirradiation; if previous RT records are unavailable, investigators can estimate the dose to previously treated tissues based on completion notes or other treatment history
Have previously been enrolled in this study or any other study investigating SM- or who have previously received any component of SM- in a clinical trial.
Previously treated with an anti-DKK therapy
Has been previously treated with an Indoleamine-,-dioxygenase- (IDO) inhibitor (e.g., epacadostat, BMS-)
Previously treated with pacritinib
Recurrent malignant gliomas previously treated with radiotherapy and/or chemotherapy
Have previously completed or withdrawn from this study or any other study investigating an ERK/ inhibitor.
The patient has previously received treatment with SL- or another investigational agent that inhibits the XPO/CRM pathway.
Previously treated with anti-pCAD biologic therapies.
Patients previously treated on clinical trial with reolysin
Patients must not have been previously treated with chemotherapy or radiation for diagnosis of lymphoma; brief (<  days) treatment with glucocorticoids is acceptable
INCLUSION - PROCUREMENT: Either previously infected with varicella zoster virus (VZV; chicken pox) or previously vaccinated with VZV vaccine
Patients who have previously received recombinant (r)IL-
Patients who have previously received either AG or venetoclax.
STRATUM C: Participants previously treated with a smoothened inhibitor must have received their last dose >  months prior to study enrollment
Currently or previously being on hydroxyurea
MCL has been previously treated and has relapsed after or progressed during prior therapy.
Patients who have previously been treated with any of the agents or same class of agents they are scheduled to receive will be excluded. For example, a patient previously treated with a PD or PDL-based therapy will not be eligible for avelumab+-BB or avelumab+OX arms. A patient previously treated with an OX based therapy will not be eligible for any of the OX single-agent or combination arms.
Subjects may have previously progressed on treatment with one of the  agents being used in this trial or treatment with other checkpoint inhibitors, as long as they have recovered from previous toxicity; subjects that previously progressed on treatment with a combination of any  of the  agents being used in this trial are eligible for the triplet cohort only
Have previously received an indoleamine- ,-dioxygenase (IDO) inhibitor.
Subjects who previously received IACS- or oxidative phosphorylation (OXPHOS) inhibitors.
Previously diagnosed with MM requiring treatment based on IMWG diagnostic criteria;
Have previously completed or withdrawn from any study investigating olaratumab.
Patients who previously participated in CH-ACM- or OOC-ACM-
Subject previously dosed with isavuconazonium sulfate.
Patients who have previously received systemic topotecan for their tumor
P-glycoprotein/ABCB inhibitors such as amiodarone, atorvastatin, azithromycin, clarithromycin; if previously on such agents, the patient must be off of it for at least two weeks prior to study treatment
Acute myeloblastic leukemia (AML) that was previously treated with HMA and is unfit for intensive chemotherapy\r\n* Patient must be within  months of prior treatment with HMA and must be willing to be treated with the same agent on this study
Subject previously treated with blinatumomab.
Subjects who received GCB systemically previously are eligible for participation
Patients should be previously untreated or have only been treated with single agent ibrutinib therapy for a period of <  months and were deemed ibrutinib intolerant
Previously treated with a maximum of  cancer-directed treatment regimens.
Patients with previously documented macular degeneration or untreated diabetic retinopathy (stable retinopathy is allowed)
Patients must not have previously undergone an intracranial LITT procedure.
Participants who have previously received ibrutinib for another indication
Have previously completed, discontinued, or have been withdrawn from this study.
Have previously received maribavir.
Has previously been treated with axitinib, AGS-CF, or AGS-MF
Scenario : No prior cdk / inhibitor; if patient has not previously received letrozole, letrozole will be supplied by Novartis; if previously progressed on letrozole, another aromatase inhibitor that the patient has not previously received is allowed, per standard of care (anastrazole or exemestane, not supplied by study); ribociclib will be supplied by Novartis; if patient has previously received letrozole, anastrazole, and exemestane, (s)he is not eligible; for scenario , patients are allowed to have started the aromatase inhibitor within  consecutive weeks prior to protocol registration; for instance, it is acceptable for patient who will be treated with letrozole in scenario #, to have started letrozole within  consecutive weeks prior to protocol registration; no prior fulvestrant allowed
Patients cannot have previously been treated with interferons (e.g., for chronic active hepatitis)
POEMS syndrome requiring therapy, previously treated or untreated
Patients previously treated with ibrutinib >  days are ineligible; if patient has been treated with ibrutinib for <  days, it must be discontinued  week ( days) weeks prior to study initiation
Patients previously treated with taxanes are excluded, unless the taxane therapy was part of an initially curative regimen (e.g. adjuvant) and was completed >  months from study enrollment; patients with previous intolerance to ramucirumab
Patients who have previously received alemtuzumab are ineligible
The subject has previously participated in this study.
Patient has previously participated in the Toca  trial (Tg --).
Subjects previously treated with CVA.
Patients with disease only in the bone previously treated with radium- will not be eligible
Patients with MDS (up to % blasts) of any risk as defined as:\r\n* Previously untreated\r\n* Previously treated with hypomethylating agent (HMA) agent; patients need to have relapsed or progressed after any number of cycles of HMA therapy; patients that do not respond to HMA therapy will also be allowed in the study; relapse or progression will be measured by International Working Group (IWG)  criteria; no response will be lack of clinical benefit after at least  cycles of HMA therapy
Patients previously treated with alectinib (Note: this only applies to the phase II portion of the study; participants entering the phase I portion of the study will still be eligible if previously treated with alectinib)
Patients with histologically or cytologically documented, unresectable, Stage IV transitional cell carcinoma of the urothelium who have not been previously treated with first-line chemotherapy.
Patients may not have previously received alisertib
Patients previously treated with immunotherapy, targeted therapy, or no therapy (treatment naive) will be eligible
NOTE: There is no exclusion for prior immune-based therapy; this includes patients previously treated on Arms  or  who are otherwise eligible for treatment on Arm  or 
Newly diagnosed Philadelphia chromosome-positive (Ph+) ALL, previously untreated, except for the below allowances:\r\n* Previously received hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (HyperCVAD) cycle A +/- cycle B\r\n* Previously received induction phase I +/- induction phase II of Berlin-Frankfurt-Munster (BFM)-modeled (pediatric or pediatric-inspired) ALL regimen\r\n* Previously received other representative (modified from HyperCVAD, BFM, or AML-like) ALL induction course, including ABL tyrosine-kinase inhibitor (TKI) plus corticosteroid\r\n* If the patient has received any of the above prior therapy, they may be enrolled, regardless of remission status
Subject previously has entered this study
Patients who have previously been treated with nivolumab and/or ipilimumab in combination with -azacytidine will be excluded
Patients with previously documented macular degeneration or untreated diabetic retinopathy (stable retinopathy is allowed)
Patients previously exposed to bosutinib are eligible unless they carry TI
Patients that previously were treated with ibrutinib for >  days
Patients who have previously been treated with systemic sonidegib or with other Hedgehog (Hh) pathway inhibitors
Patients who have previously been treated with systemic LDE or with other hedgehog pathway inhibitors
The patient has previously received definitive surgical, radiation, or chemoradiation treatment for HNSCC
Note: patients who have previously received ipilimumab and have documented gastrointestinal (GI) toxicity must have a normal colonoscopy with normal colonic biopsies
Patients previously treated with immunotherapy, targeted therapy, or no therapy (treatment naive) will be eligible (Turnstile I)
Patients who have previously taken omega- fatty acid within  month prior to study enrollment
The subject has previously been treated for the primary diagnosis of OP-SCCA or SG-SCCA
Patients previously treated with RUX or AZA (only applicable for the MF and MDS/MPN arms)
Previously treated participants
Patients previously treated with immunotherapy, targeted therapy, or no therapy will be eligible; patients receiving cytotoxic agents will be evaluated by the PI or his designee
Patients previously treated with immunotherapy, targeted therapy, or no therapy will be eligible; patients receiving cytotoxic agents will be evaluated by the PI or his designee as to suitable eligibility (Turnstile I)
Previously untreated and treated patients are eligible
Patients previously treated with TLR-/ agonist treatment.
Treated with hydroxyurea within  days;
Subjects previously treated with enzyme-induced antiepileptic drugs (EIAEDs) must have discontinued treatment with these agent(s) greater than or equal to  weeks prior to enrollment.
Previously treated ALL including philadelphia chromosome (BCR-Ab) positive ALL who meet all of the following criteria: \r\n* Diagnosis of CD-positive B-cell ALL based on the flow cytometry and histology \r\n* Previously treated subjects with primary refractory disease OR after first or subsequent relapse \r\n* Subjects with detectable lymphoblasts in bone marrow (BM) or extramedullary disease (EMD) that is radiographically measurable and amenable to repeat biopsies
Women treated previously with -fluorouracil or imiquimod or other medications for high-grade squamous intraepithelial lesions will be excluded from the study
Patients may have previously failed non-platinum containing therapy or may never have previously progressed on treatment
Previously diagnosis of alpha- or beta-thalassemia since these patients may have significantly higher PK levels than patients without these disorders
Active intracranial metastases; patients with previously resected intracranial disease and/or previously irradiated intracranial metastases that have been clinically stable for four weeks are eligible
Group  - patients must have pathologically documented, definitively diagnosed locally advanced or metastatic NSCLC with a RET rearrangement that was not previously treated with a TKI that inhibits RET.
Have previously received maribavir.
Patients who have been previously treated with inotuzumab ozogamicin
Participants may not have been vaccinated previously with any of the synthetic peptides included in this protocol
Patients who have previously been treated with eribulin are allowed to participate in the microdialysis portion of the study only
Subjects who have previously received anetumab ravtansine
Have previously completed or withdrawn from this study or any other study investigating dasatinib; prior treatment with other tyrosine kinases, including afatinib, is acceptable
All laboratory and imaging studies must be completed and satisfactory within  days of signing the consent document, with the exceptions of: negative serum pregnancy test for women of child-bearing potential which must be negative within  days of screening, human leukocyte antigen (HLA)-typing which will not be repeated if performed previously, and pulmonary function tests (PFTs)/cardiac stress tests whose results are valid for  months if performed previously
Patients may be treatment-naive or may have been previously treated for metastatic disease
All laboratory and imaging studies must be completed and satisfactory within  days of signing the consent document, with the exceptions of: negative serum pregnancy test for women of child-bearing potential must be negative within  days of starting vemurafenib, human leukocyte antigen (HLA)-typing which will not be repeated if performed previously, and pulmonary function test (PFTs)/cardiac stress tests whose results are valid for  months if performed previously
previously received:
Subject has been previously treated with LifeSeal Surgical Sealant.
Without confirmed stability over  days in patients previously treated with prior surgery or radiation; OR
The patient has previously received treatment with SL-.
Subjects who have previously undergone intraperitoneal chemotherapy
Previously received XP-
Subject has been previously treated with mogamulizumab;
Have previously completed or withdrawn from this study or any other study investigating LY or other Notch inhibitors.
Without confirmed stability over  days in patients previously treated with prior surgery or radiation; OR
HER-/neu negative or, if HER-/neu positive, disease must have previously progressed on treatment with trastuzumab
Participants previously treated in the recurrent/metastatic setting with any  of the  SOC therapies in this study (i.e., docetaxel, capecitabine, or gemcitabine) may not receive the same therapy if randomized to the SOC arm. Additionally, participants previously treated in the recurrent/metastatic setting with all  SOC therapies are excluded from this study.
Received glembatumumab vedotin (CR-vcMMAE; CDX-) or other MMAE-containing agents previously.
were previously treated with CD-targeted therapy or IMiDs (e.g. thalidomide, LEN)
Subjects must have previously completed standard radiation therapy and been exposed to temozolomide. Patients must be in first or second relapse.
Patients must have been previously treated with a taxane except in cases of contraindication (e.g. poor performance status, age or patient choice)
Patients who have previously been treated with cytotoxic chemotherapy; however, patients who received prior low-dose methotrexate for treatment of an ectopic pregnancy will be eligible for this study
Patients with previously documented macular degeneration or diabetic retinopathy
Patients previously treated with irinotecan-containing regimen
Subject who was previously treated with at least one prior systemic chemotherapy, immunotherapy, or chemoimmunotherapy.
Patients must have been previously treated, as defined by treatment with at least one prior cytotoxic regimen or agent
Has been previously treated with a Bromodomain and Extra-Terminal (BET) inhibitor
Patients may not have received eribulin or lenvatinib previously
Patients who have been previously treated in the adjuvant setting for melanoma will be eligible for treatment after a  day wash-out period
Patients who have received trabectedin (Yondelis, ET-) or participated in the phase III clinical study of trabectedin NCT previously will not be eligible
Previously treated with an anti-Dkk- therapy.
Patient was previously exposed to PBI .
Patients must be ipilimumab-eligible. (This includes: ) patients previously untreated with ipilimumab; ) patients previously treated (more than  year previously) with ipilimumab using a route of administration other than intravenous infusion; and ) patients previously treated with antitumor agents other than intravenous ipilimumab).
Patients who were previously treated with ipilimumab administered by intravenous infusion.
History of previously treated smoldering myeloma
Untreated or previously treated for Waldenstrm's macroglobulinemia. Previously treated subjects must have either documented disease progression or had no response (stable disease) to the most recent treatment regimen.
Currently or previously treated with ruxolitinib for PMF or Post-PV/ET MF for at least  days, and characterized by
Subjects who have received radiation to the orbit at any time previously
Cholangiocarcinoma subjects must have radiographically measurable disease in at least one site not previously treated with radiation, chemoembolization, radioembolization, or other local ablative procedures; a new area of tumor progression within or adjacent to a previously-treated lesion, if clearly measurable by a radiologist, is acceptable.
Subjects must have radiographically measurable disease in at least one site not previously treated with radiation, chemoembolization, radioembolization, or other local ablative procedures; a new area of tumor progression within or adjacent to a previously-treated lesion, if clearly measurable by a radiologist, is acceptable.
Patients who have not previously been treated with HMA therapy will be excluded
Participants previously treated with bendamustine only if their duration of response was >/=  months
Prior malignancy except previously diagnosed and definitively treated more than  years prior to trial or whose prognosis is deemed good enough to not warrant surveillance
BCC/SCC that was previously treated (i.e., recurrent BCC/SCC)
Patients who have previously provided samples at any time after trastuzumab resistance will be exempt from biopsy at the start of therapy
COHORT II: Patients must not have previously received treatment with chemotherapy for MM
Patients who have been previously treated with bendamustine plus rituximab (BR) are eligible, provided they did not progress during or within  months of completing BR treatment
In the Phase  portion of the trial only, subjects who have previously received treatment with an inhibitor of IDH.
Patients with previously documented macular degeneration or diabetic retinopathy are ineligible
Previously treated SCLC with only one prior treatment regimen (cyclophosphamide/doxorubicin/vincristine [CAV] alternating with etoposide/cisplatin [EP] is acceptable)
Previously received eribulin.
For Part  of the Study only, patients must have measurable disease by RECIST . and be in one of the the groups below. Patients in groups , , ,  and  may not have been previously treated with BRAF and/or MEK inhibitors
Prior therapy allowed: \r\n* Patients may have been previously treated with up to three regimens of oral multikinase inhibitors, including sorafenib, sunitinib and pazopanib\r\n* Patients may have been previously treated with external beam radiation or cytotoxic chemotherapy therapy
Patients may not have been treated with prior sipuleucel-T
Currently or previously treated with AMG , or other molecules that inhibit the angiopoietins or Tie receptor
Use previously of intra-articular treatment within  weeks prior dosing.
Previously treated with ponatinib
Retreatment of previously irradiated tumor will be excluded; this will in general be described as an anticipated overlap of a region that has previously received >=  Gy and would now be included within the D region of the SBRT plan; there is no restriction on prior stage as long as dosimetry guidelines can be met
Indications B - LMS: Subjects previously treated with at least one prior line of approved therapy.
Previously treated with a maximum of four unique chemotherapy containing treatment regimens
Patients must have been previously treated with trastuzumab in any setting (which may have been previously administered with or without pertuzumab)
Patients who previously discontinued trastuzumab due to unacceptable cardiac toxicity
RAS (KRAS/NRAS) wild type mCRC not previously treated with an anti-EGFR containing regimen (unless contraindicated or not considered standard practice per clinical site or country guidelines).
Patients previously treated with eculizumab for TAM.
Previously enrolled and treated for at least  months in Study NEOD-
Subject has received ASP previously.
Herceptin: women who have been previously treated with Herceptin or other monoclonal antibody therapies are eligible for the trial
Currently or previously treated with biologic, or immunotherapy
Patients who have previously received treatment with ibrutinib (modified by amendment ), including:
Previously-treated with any conditioning regimen and any GVHD immune suppression prophylaxis and formulation of steroids, except as noted in Exclusion Criteria #.
Patients who have previously been treated with IMGN
Patients must be untreated or have had only one prior chemotherapy regimen for ALL or LL; previously treated patients will be analyzed separately
COHORT  ONLY: A Smoothened inhibitor must have been previously administered as monotherapy
Patients may not previously have received irinotecan, topotecan or other topoisomerase I inhibitor
Previously received photodynamic therapy for cholangiocarcinoma
Previously undergone metal stent insertion
Patients previously treated with sunitinib or crizotinib
Tumor must not have been treated previously with radiation
Subjects previously treated on another investigational agent must have a -week or more washout before starting cabozantinib, depending on the agent, toxicity profile, and half-life; however, such patients may begin tetracycline dosing after consent is signed
Has previously received XP-.
Treated with trastuzumab Part c:
Subjects must have received treatment for CLL with chemotherapy agents or antibodies OR if subjects are previously untreated they must state in the consent form that they are refusing to be treated with chemotherapy or antibodies
Subjects previously treated with a systemic photosensitizer within  months of screening date
Patients who have previously received CDX- (glembatumumab vedotin) or other monomethyl auristatin E (MMAE)-containing agents
Prior treatment with sirolimus, cyclophosphamide or topotecan: patients previously treated with any of these drugs as single agents will be eligible for this study; patients previously treated with two of the three drugs will also be eligible, however patients previously treated with all three agents in combination will not be eligible; patients previously treated with sirolimus analogues (e.g. temsirolimus, everolimus, or ridaforolimus) are also eligible
Previously untreated AML (except: emergency leukopheresis and/or hydroxyurea during the screening phase to control hyperleukocytosis but must be discontinued at least one day prior to start of study therapy)
Patients who have previously been treated with LDE or other hedgehog (Hh) pathway inhibitors
Patients who have previously received eribulin, halichondrin B, or analogues of halichondrin B
Subjects who had been treated with ADI-PEG  previously.
Patients who have previously received romidepsin or Abraxane
Patients with known human immunodeficiency virus (HIV) or Hepatitis B or C (active, previously treated or both), a history of solid organ or bone marrow transplantation would generally be considered to have met exclusion criteria, however exceptions may be considered on a case-by-case basis by the medical monitor.
Subjects that have previously been treated with a veliparib.
Have previously been exposed to MGAH in this or any other trial
Previously treated; NOTE: no limit to prior therapy provided there is adequate residual organ function
Subjects who had been treated with ADI-PEG  previously.
The patient previously received treatment with SL-.
Patients previously treated with systemic chemotherapy will be eligible
GIST subjects must have previously received all FDA-approved therapies (imatinib mesylate, sunitinib malate, and regorafenib) for which they are eligible
Patients who have previously been treated with systemic LDE or with other Hh pathway inhibitors
Maintenance of Lupron or antagonist unless previously treated with orchiectomy
Patients must have recurrent SCCHN that has been previously treated with cetuximab as part of potentially curative therapy (i.e. with induction therapy, radiotherapy or chemoradiotherapy); the interval from completion of cetuximab and study treatment should be >  months
Subjects that have previously been treated with dacarbazine or its analogue temozolomide or eribulin.
Patients who have previously received treatment with LY
If previously treated with bortezomib (alone or in combination), progression during treatment
If previously treated with a lenalidomide and dexamethasone (len/dex) combination:
Patients who previously participated in or are currently participating in another intervention clinical trial designed to improve adherence
Patients previously treated with radioactive isotope (e.g. strontium [Sr]) within  days of randomization
Previously enrollment in this study
Patients with a feeding tube previously placed
Patients previously treated with anti-GITR therapy.
Patients must have previously undergone or plan to undergo thyroidectomy; for those patients who have previously undergone surgery, pre-operative labs, including complete blood cell count with differential must be available
All subjects previously discontinued from an elotuzumab study for any reason
Survivors must not have previously received an SCP or are unwilling to receive one
No prior chemotherapy or radiation therapy for osteosarcoma; subjects who develop osteosarcoma as a second cancer are eligible if they have not previously received cisplatin, doxorubicin or other anthracyclines, or MTX
PATIENTS: Previously screened and with greater than  level of psychological distress
Parents of childhood cancer survivors who are now  years or older and who were previously treated for ALL or AML (do not need to live with the child)
Patients who may have previously received SP-SAP on the study
Patients may have been previously treated or previously untreated
Patients may have previously received other chemotherapy
Patients who have previously been treated with systemic LDE or with other Hedgehog (Hh) pathway inhibitors
Subjects who have previously completed primary treatment for a gynecologic malignancy
Will be treated according to the Armstrong method
Patients who previously participated in this study and are returning to the Womens Imaging Center for follow-up diagnostic tests
Phase I: Previously screened or not screened
Patients who have been previously vaccinated with vaccinia
Has previously participated in this study, has previously received bezlotoxumab, has received an experimental monoclonal antibody against C. difficile toxin B, or has received a vaccine directed against C. difficile or its toxins.
Patients who have previously received SCH
Subject is diagnosed with neuroblastoma, hepatoblastoma, osteosarcoma or extracranial germ cell tumors and has not been previously treated with cisplatin or carboplatin.
Has previously participated in a MK- (letermovir) study
Liver nodule previously treated with trans-arterial or thermal ablation
Previously diagnosed high-grade tracheal obstruction
Have a previously diagnosed condition of dry mouth
Have a previously diagnosed condition of gum disease this included gingivitis, gingival bleeding and plaque
Patient has previously participated in this study.
Patient has previously received [F]NaF in the last thirty days
Previously treated with any prior mIDH targeted therapy
Have not previously viewed the Pathways decision aid
Tumor previously treated with radiation therapy
Has locally recurrent inoperable breast cancer not previously treated with chemotherapy and which cannot be treated with curative intent OR has metastatic breast cancer not previously treated with chemotherapy.
